Connect with us


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Expects To Launch Clinical Trial For A Modified Caumz To Treat Hepatocellular Carcinoma In Q1 2020



Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has announced the receipt of US FDA Orphan Drug Designation for delta 9 THC to cure hepatocellular carcinoma. Chief Regulatory Officer and Chief Executive Officer of Tetra Bio, Dr. Guy Chamberland, said the company is excited to receive orphan drug designation for THC from FDA. It recognizes the innovation and drug development program that will comprise hepatocellular carcinoma.

Clinical trials of a modified formulation of Caumz

Guy said the company plans to launch the clinical trial of the modified formulation of Caumz on Q1 2020 to treat hepatocellular carcinoma. The company already received a license for the IP and formulation technology for the selective release of cannabinoids to cure brain cancers. It will use the data collected from the clinical trial 1 of Caumz to support the phase 2 clinical trial of the modified formulation of Caumz. The phase 2 clinical trial will be conducted on patients suffering from hepatocellular carcinoma in advanced stages.

Guy said he is pleased to conduct phase 2 clinical trials for this advanced cancer therapy with no additional spending for the investors. The company will focus on developing inhaled cannabinoid drugs and introduce another drug soon.

Signs a deal to commercialize Caumz in Mexico

Tetra Bio signed a deal with Alternavida SA for the distribution, co-development, and marketing of Caumz in Mexico. Guy said the vision of Alternavida to open the clinical site to conduct clinical trials with the drug – Caumz and applying for approval testifies the leadership of Tetra Bio as a pharmaceutical company to provide wellness and health benefits to Mexicans.

According to Guy, Alernavida showed interest to partner with Tetra Bio to develop and launch Caumz. He stated the relationship with Alternavida would strengthen in the coming years and expect to work together to bring innovative medicines to Mexicans.

As per the terms of the deal, Alternavida will fund the clinical trials in Mexico for fibromyalgia and Serenity trials. The company will collaborate on the development of Caumz. It is responsible for registration and commercializing the drug in Mexico. The clinical trial sites, which are FDA and Health Canada compliant, will be up and functional in 2020. The firms will achieve cost savings of $10 million CAD for this program.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.